Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Donaustauf – page 5

349 clinical trials in Donaustauf, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Donaustauf at a glance
349
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

349 trials in Donaustauf

Open in trial search

Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Efficacy of efanesoctocog alfa in reducing synovitis in patients with congenital hemophilia A – a multicenter, randomized, open‑label phase 3 trial

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efanesoctocog Alfa
  • Sponsor:GWT-Tud GmbH

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Incyte Corp.

Neoadjuvant Sacituzumab Govitecan and Pembrolizumab for Patients with Clinical Stage II-III Triple-Negative Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:WSG Women's Cancer Study Group GmbH

Neoplasm

Recruiting

Volrustomig in Patients with Unresectable Pleural Mesothelioma and Esophageal Squamous Cell Carcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Cisplatin
  • Sponsor:AstraZeneca AB

A study comparing BGB-11417 and zanubrutinib with venetoclax and acalabrutinib for patients with previously untreated chronic lymphocytic leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:BeOne Medicines I GmbH

Colon cancer

Recruiting

A study to evaluate the safety and effectiveness of darizmetinib hydrochloride in patients who have had liver surgery due to colon cancer metastases

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Darizmetinib hydrochloride
  • Sponsor:HepaRegeniX GmbH

Bladder cancer

Recruiting

A study of sacituzumab tirumotecan versus docetaxel, paclitaxel, or vinflunine for patients with pretreated advanced or metastatic bladder cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Merck Sharp & Dohme LLC

A study of rilvegostomig and ramucirumab in patients with advanced or metastatic non-small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ramucirumab
  • Sponsor:AstraZeneca AB

A study of LY4268989 and mirikizumab in adults with moderately to severely active ulcerative colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Mirikizumab
  • Sponsor:Eli Lilly & Co.

A study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ABBV-142
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Donaustauf

What the registry says about research in the country

01 Pulmonary Research

Clinical investigations focusing on idiopathic pulmonary fibrosis (IPF), a progressive lung condition that affects respiratory function. These trials aim to evaluate new therapeutic approaches for improving lung function in affected patients.

  • Respiratory Function Assessment
  • Treatment Response Evaluation
  • Dose-Response Analysis

Research efforts include comparative studies between various treatment doses and placebo to determine optimal therapeutic effectiveness for patients with pulmonary conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.